Vasculature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer.

Publication Type:

Journal Article


The Prostate, Volume 68, Issue 10, p.1105-15 (2008)


2008, androgens, Animals, Antibiotics, Antineoplastic, Cell Division, Clinical Research Division, Disease Models, Animal, Doxorubicin, Drug Therapy, Combination, Male, MICE, Mice, Inbred C57BL, Mice, Transgenic, Neovascularization, Pathologic, Prostatic Neoplasms, Receptors, Androgen, Tumor Necrosis Factor-alpha


Poor penetration and uneven distribution of doxorubicin in tumors limits the efficacy of this drug in patients with prostate cancer (PC). Aim of the study was to investigate whether pre-treatment with NGR-TNF, a tumor necrosis factor-alpha derivative able to target tumor vessels and alter vessel permeability, increases the penetration and the efficacy of doxorubicin in pre-clinical models of PC.